Xulong Chen

Dr. Xulong Chen


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Open Chemistry
Verified
Journal Article
Open access
PDF file
CLCheng Li
Cheng Li
ANAbid Naeem
Abid Naeem
JSJiangwen Shen
Jiangwen Shen
WZWeiwei Zha
Weiwei Zha
QZQingyun Zeng
Qingyun Zeng
XCXulong Chen
Xulong Chen
Curcumin is an isolated phytopolyphenol pigment found in the Curcuma longa, commonly known as turmeric, with various pharmacological properties. It has many effects, including anti-tumour, anti-inflammatory, anti-bacterial, anti-oxidation, and hypoglycemic properties. However, due to its oral bioavailability, the use of the drug in the clinical environment is limited. Moreover, curcumin’s low bioavailability is attributed to its insoluble nature, poor permeability, and inhibition of P-glycoprotein efflux and enzyme metabolism. Several new dosage forms of curcumin have been developed based on its physical properties to improve oral administration. However, the curcumin oral administration system still needs to be improved from the perspective of both research and clinical applications.

1 January 2023 in Open Chemistry
Verified
Journal Article
Open access
PDF file
CLCheng Li
Cheng Li
HJHongli Jiang
Hongli Jiang
JYJingchun Yao
Jingchun Yao
XCXulong Chen
Xulong Chen
PTPuxun Tian
Puxun Tian
Radix puerariae has become the most commonly used medicine for diabetic nephropathy (DN). However, the mechanism of Radix puerariae in the treatment of DN is not completely clear. This study is to determine the active ingredients, targets, and signaling pathways of Radix puerariae for the treatment of DN using network pharmacology analysis and animal experiments to confirm its possible mechanism of action. A total of 12 potential effective components and 10 key therapeutic targets were obtained. The Kyoto Encyclopedia of Genes and Genomes enrichment analysis indicated that the use of Radix puerariae in DN treatment mainly involves HIF-1 signaling pathway, TNF signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, FoxO signaling, and VEGF signaling pathway. Molecular docking proved that the combined activity of the components with potential key targets were excellent. Animal experiments showed that Radix puerariae could improve the renal pathological structure in DN rats. Radix puerariae could decrease the content of AKT1, IL-6, INS, and reduce the expression levels of p-Akt/Akt and p-FoxO1/FoxO1 in renal tissue of DN rats. This study provides insight into the therapeutic potential and molecular mechanisms of Radix puerariae for treating DN.

13 July 2026 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
JXJun Xiao
Jun Xiao
TXTian Xu
Tian Xu
YFYanfang Fu
Yanfang Fu
JXJing Xia
Jing Xia
ZCZhiying Chen
Zhiying Chen
XCXulong Chen
Xulong Chen
Cognitive impairment (CI) in dialysis patients is a common and serious complication that significantly affects prognosis, with lack of effective treatment strategies. However, its mechanisms are still not fully clear, and effective treatment strategies are still limited. In recent years, more evidence has suggested that gut microbiota dysbiosis and changes in gut-derived metabolites may be involved in the development of CI in dialysis patients through the microbiota-gut-kidney-brain axis. Recent studies have shown that gut microbiota dysbiosis in dialysis patients may promote the progression of CI through several pathways. These include the accumulation of gut-derived uremic toxins, such as indoxyl sulfate (IS), p-cresyl sulfate (PCS), and Trimethylamine N oxide (TMAO), changes in bile acid metabolism; and the reduction of short-chain fatty acids (SCFAs) with neuroprotective effects. These changes may damage the intestinal barrier and the blood–brain barrier (BBB), and promote systemic inflammation, oxidative stress, and neuroinflammation. As a result, cognitive dysfunction in dialysis patients may be further aggravated. Therefore, targeting the gut microbiota has become a promising treatment direction. These strategies include dietary intervention, probiotics and related preparations, fecal microbiota transplantation (FMT), and targeted removal of uremic toxins and their derivatives. This review summarizes the gut microbiota composition associated with CI in dialysis patients, examines the molecular mechanisms of injury mediated by the microbiota–gut–brain–kidney axis, evaluates current microbiota-targeted interventions, and discusses future research directions for improving clinical prevention and treatment.